A Phase 1/2 Study of ASP1570 in Participants with Locally Advanced or Metastatic Solid Tumors
NCT #
NCT05083481
Condition(s)
Lung Cancer (NSCLC), Skin Cancer/ Melanoma, Solid Tumor
Molecular Target(s)
DAG (DGK)
Drug Classification(s)
Immunotherapy (Targeted), Small Molecule
Agents(s)
ASP1570
Phase(s)
I
Mechanism of Action
ASP1570 is a small molecule immuno-oncology agent that is expected to act through the activation of immune cells in the tumor microenvironment.
Purpose
- How much of the study drug can be given alone and in combination with Pembro with an acceptable level of side effects
- The effects of the study drug alone and in combination with Pembro (good and bad)
- How much of the study drug alone and in combination with Pembro is absorbed into the blood and how fast it is removed
- If the study drug alone and in combination with Pembro prevents or slows tumor growth or shrinks existing tumors
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.